FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296201432> ?p ?o ?g. }

• W4296201432 endingPage "106456" @default.
• W4296201432 startingPage "106456" @default.
• W4296201432 abstract "The development of tumor therapeutic resistance is one of the important reasons for the failure of antitumor therapy. Starting with multiple targets and multiple signaling pathways is helpful in understanding the mechanism of tumor resistance. The overexpression of prolyl isomerase Pin1 is highly correlated with the malignancy of cancer, since Pin1 controls many oncogenes and tumor suppressors, as well as a variety of cancer-driving signaling pathways. Strikingly, numerous studies have shown that Pin1 is directly involved in therapeutic resistance. In this review, we mainly summarize the functions and mechanisms of Pin1 in therapeutic resistance of multifarious cancers, such as breast, liver, and pancreatic carcinomas. Furtherly, from the perspective of Pin1-driven cancer signaling pathways including Raf/MEK/ERK, PI3K/Akt, Wnt/β-catenin, NF-κB, as well as Pin1 inhibitors containing juglone, epigallocatechin-3-gallate (EGCG), all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), it is better to demonstrate the important potential role and mechanism of Pin1 in resistance and sensitization to cancer therapies. It will provide new therapeutic approaches for clinical reversal and prevention of tumor resistance by employing synergistic administration of Pin1 inhibitors and chemotherapeutics, implementing combination therapy of Pin1-related cancer signaling pathway inhibitors and Pin1 inhibitors, and exploiting novel Pin1-specific inhibitors." @default.
• W4296201432 created "2022-09-18" @default.
• W4296201432 creator A5001317242 @default.
• W4296201432 creator A5037458498 @default.
• W4296201432 creator A5063091185 @default.
• W4296201432 creator A5081130170 @default.
• W4296201432 creator A5090113807 @default.
• W4296201432 date "2022-10-01" @default.
• W4296201432 modified "2023-10-16" @default.
• W4296201432 title "Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies" @default.
• W4296201432 cites W1139788413 @default.
• W4296201432 cites W1491450961 @default.
• W4296201432 cites W1541929695 @default.
• W4296201432 cites W1549328326 @default.
• W4296201432 cites W1724078287 @default.
• W4296201432 cites W1964898641 @default.
• W4296201432 cites W1967130690 @default.
• W4296201432 cites W1968069432 @default.
• W4296201432 cites W1969486448 @default.
• W4296201432 cites W1971085650 @default.
• W4296201432 cites W1973304938 @default.
• W4296201432 cites W1981149222 @default.
• W4296201432 cites W1981599964 @default.
• W4296201432 cites W1983661438 @default.
• W4296201432 cites W1985131241 @default.
• W4296201432 cites W1985445337 @default.
• W4296201432 cites W1985603233 @default.
• W4296201432 cites W1991904087 @default.
• W4296201432 cites W1993442614 @default.
• W4296201432 cites W1996583924 @default.
• W4296201432 cites W2001369536 @default.
• W4296201432 cites W2004906639 @default.
• W4296201432 cites W2016132261 @default.
• W4296201432 cites W2018163822 @default.
• W4296201432 cites W2021577502 @default.
• W4296201432 cites W2023546573 @default.
• W4296201432 cites W2030353291 @default.
• W4296201432 cites W2030367200 @default.
• W4296201432 cites W2033228930 @default.
• W4296201432 cites W2038805839 @default.
• W4296201432 cites W2045216597 @default.
• W4296201432 cites W2056250446 @default.
• W4296201432 cites W2057753121 @default.
• W4296201432 cites W2059977521 @default.
• W4296201432 cites W2071760372 @default.
• W4296201432 cites W2076485183 @default.
• W4296201432 cites W2081673273 @default.
• W4296201432 cites W2088157280 @default.
• W4296201432 cites W2090248730 @default.
• W4296201432 cites W2093402539 @default.
• W4296201432 cites W2093914407 @default.
• W4296201432 cites W2095001952 @default.
• W4296201432 cites W2096789813 @default.
• W4296201432 cites W2100347281 @default.
• W4296201432 cites W2108177844 @default.
• W4296201432 cites W2108459871 @default.
• W4296201432 cites W2116528837 @default.
• W4296201432 cites W2118502374 @default.
• W4296201432 cites W2121847612 @default.
• W4296201432 cites W2123198444 @default.
• W4296201432 cites W2126043496 @default.
• W4296201432 cites W2128846014 @default.
• W4296201432 cites W2129876170 @default.
• W4296201432 cites W2130861650 @default.
• W4296201432 cites W2132385852 @default.
• W4296201432 cites W2132527654 @default.
• W4296201432 cites W2135803007 @default.
• W4296201432 cites W2140783564 @default.
• W4296201432 cites W2149221810 @default.
• W4296201432 cites W2155239200 @default.
• W4296201432 cites W2165804364 @default.
• W4296201432 cites W2167451931 @default.
• W4296201432 cites W2170109143 @default.
• W4296201432 cites W2238256203 @default.
• W4296201432 cites W2265419075 @default.
• W4296201432 cites W2290709758 @default.
• W4296201432 cites W2298793375 @default.
• W4296201432 cites W2315613727 @default.
• W4296201432 cites W2337153276 @default.
• W4296201432 cites W2397216094 @default.
• W4296201432 cites W2412103425 @default.
• W4296201432 cites W2416176918 @default.
• W4296201432 cites W2508385150 @default.
• W4296201432 cites W2522227709 @default.
• W4296201432 cites W2538216694 @default.
• W4296201432 cites W2550327713 @default.
• W4296201432 cites W2581145348 @default.
• W4296201432 cites W2593409368 @default.
• W4296201432 cites W2604862718 @default.
• W4296201432 cites W2605400647 @default.
• W4296201432 cites W2606001457 @default.
• W4296201432 cites W2748116562 @default.
• W4296201432 cites W2753000927 @default.
• W4296201432 cites W2756028785 @default.
• W4296201432 cites W2765648460 @default.
• W4296201432 cites W2765777951 @default.
• W4296201432 cites W2768564401 @default.
• W4296201432 cites W2774445945 @default.

• next